Fewer than one in 10 individuals who could benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it issues its initial guidance on the medications.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to these injectable treatments.
According to estimates, more than two billion could be living with obesity by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a chronic disease that can be treated with thorough and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant barriers to broad availability to the treatments that can help people shift significant weight, explains the body.
Skinny Jab Scarcity
Despite the present most favorable case, the supply of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation encourages countries and companies to expand availability, via measures like licensing agreements.
Exclusive production rights on semaglutide – the primary component of a leading brand – is due to expire in several countries in 2026.
The Way Weight-Loss Drugs Operate
These medications replicate a body's own hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so users eat less.
Individuals typically start to lose weight after several weeks of starting on the regular doses.
Research indicates patients may regain a significant portion within a year of halting the drug, because their typical food cravings return.
To be above a healthy weight increases your chance for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity affects people in every country and was associated with millions of deaths worldwide in 2024, per the health agency.
